Background Sarcoidosis is a chronic granulomatous disease characterized by non-caseating granuloma formation. Galectin-3 is a multifunctional protein involved in many biological processes such as fibrosis, angiogenesis and immune activation.
Objectives To determine the serum galectin-3 and transforming growth factor-beta (TGF-beta) levels in patients with sarcoidosis and to determine a possible correlation with clinical findings.
Methods Forty-four biopsy proven sarcoidosis patients followed at a single center and age and sex matched 41 healthy volunteers were included in the study. Demographic, clinical, laboratory and radiological data were recorded in all patients. Serum galectin-3 and TGF-beta levels were measured by ELISA method.
Results Among 44sarcoidosis patients 13 (29.5%) were male and 31 (70.5%) were female. Average patient age was 47.4 years, mean disease duration was 3.2year. Twenty-one (47.7%) patients had erythema nodosum, three (6.8%) had uveitis, 40 (90.9%) had arthralgia, 23 (52.3%) had ankle arthritis, 15 (34.1%) had enthesitis. Laboratory evaluation showed increased serum ACE level in 24 (54.5%) patients, increased serum calcium level in 11 (25%) patients, increased serum D3 level in 5 (11.4%) patients, increased ESR and CRP levels in 22 (50%) and 23 (52.3%) patients, respectively. Serum galectin-3 level were similar in the sarcoidosis patients and the control group (p=0.977). No relationship were found between serum galectin-3 level and clinical and laboratory findings (p>0.05). Serum TGF-beta level were higher in patients with sarcoidosis compared with the control group (p=0.005). Serum TGF-beta level was associated only with enthesitis and arthralgia (p=0.006,p=0.02), while no correlation were detected with other disease features (p>0.05).
Conclusions We found high level of serum TGF-beta, but normal level of galectin-3 in patients with sarcoidosis. These findings suggest that TGF-beta play an important role in the pathogenesis of sarcoidosis. to, there is a need for new Multicenter prospective studies are needed to illuminate the possible relationship between serum galectin-3 and sarcoidosis.
Disclosure of Interest None declared